Premature treatment discontinuation in HIV/HCV- coinfected patients receiving pegylated interferon plus weight-based ribavirin

Background: Chronic hepatitis C therapy in HIV patientsis often penalized by more frequent premature treatmentdiscontinuations. It is unclear what the relative contribu-tion of more adverse events and/or early virologicalfailures are.Methods: PRESCO was a prospective, multicentre,comparative trial, in which 389 HIV/HCV-coinfectedpatients with CD4